Table S32: Percent of IgD- B cells that are IgG+ magnitude testing between selected time points for the treatment groups. Testing was done using Wilcoxon signed-rank test for paired data (two-sided, $\alpha = 0.05$) and p values less than 0.05 are highlighted.

	Number of Pairs	Median (Range)	P Value
20µg			
Wk-4 (V02) vs. Wk3 (V05)	16	46.4807 [21.9120, 63.2837] vs. 51.5076 [36.3084, 65.2150]	0.2312
Wk-4 (V02) vs. Wk4 (V06)	18	46.4807 [21.3294, 63.2837] vs. 46.5943 [17.0214, 62.8927]	0.8650
Wk-4 (V02) vs. Wk8 (V07)	18	46.4807 [21.3294, 63.2837] vs. 48.1413 [19.2856, 61.7844]	1.0000
Wk-4 (V02) vs. Wk10 (V08)	17	47.2515 [21.3294, 63.2837] vs. 49.0220 [20.0712, 62.0421]	0.6112
Wk-4 (V02) vs. Wk11 (V09)	14	46.4807 [21.9120, 63.2837] vs. 55.3841 [46.7749, 73.4127]	0.0023
Wk-4 (V02) vs. Wk16 (V10)	18	46.4807 [21.3294, 63.2837] vs. 46.0667 [18.9283, 63.2096]	0.4171
Wk8 (V07) vs. Wk10 (V08)	17	48.4408 [19.2856, 61.7844] vs. 49.0220 [20.0712, 62.0421]	0.5171
Wk8 (V07) vs. Wk11 (V09)	14	48.1413 [22.3488, 61.7844] vs. 55.3841 [46.7749, 73.4127]	0.0017
Wk8 (V07) vs. Wk16 (V10)	18	48.1413 [19.2856, 61.7844] vs. 46.0667 [18.9283, 63.2096]	0.1964
100µg			
Wk-4 (V02) vs. Wk3 (V05)	16	50.7073 [34.8729, 66.7960] vs. 46.9267 [22.7768, 66.1065]	0.4332
Wk-4 (V02) vs. Wk4 (V06)	18	50.7073 [19.9276, 66.7960] vs. 49.5157 [20.1457, 65.7795]	0.3927
Wk-4 (V02) vs. Wk8 (V07)	17	51.8966 [19.9276, 66.7960] vs. 51.5263 [18.5166, 66.7367]	0.4038
Wk-4 (V02) vs. Wk10 (V08)	17	51.8966 [19.9276, 66.7960] vs. 52.8263 [20.4023, 68.0319]	0.0093
Wk-4 (V02) vs. Wk11 (V09)	14	50.7073 [34.8729, 66.7960] vs. 58.7416 [26.3119, 70.7053]	0.0419
Wk-4 (V02) vs. Wk16 (V10)	16	50.7073 [19.9276, 62.5092] vs. 49.4197 [22.0835, 63.7409]	0.8999
Wk8 (V07) vs. Wk10 (V08)	17	51.5263 [18.5166, 66.7367] vs. 52.8263 [20.4023, 68.0319]	0.0004
Wk8 (V07) vs. Wk11 (V09)	14	51.1829 [38.3040, 66.7367] vs. 58.7416 [26.3119, 70.7053]	0.0494
Wk8 (V07) vs. Wk16 (V10)	16	51.1829 [18.5166, 62.3137] vs. 49.4197 [22.0835, 63.7409]	0.2114